Nivolumab Therapy for Treatment-Related Vitiligo in a Patient With Relapsed Metastatic Melanoma

Melanoma and Skin Cancer

Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors

Br J Dermatol.

Gault A, Anderson AE, Plummer R, Stewart C, Pratt AG, Rajan N

doi: 10.1111/bjd.19750.Visit the original publication at ncbi.nlm.nih.gov

Melanoma and Skin CancerImmunotherapy

Neoadjuvant Immunotherapy with combined Ipilimumab and Nivolumab in Melanoma Patients with Primary or In-transit Disease

Br J Dermatol.

Weber J, Glutsch V, Geissinger E, Haug L, Lock JF, Schneider F, Kneitz H, Goebeler M, Schilling B, Gesierich A

doi: 10.1111/bjd.18739.

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Acquired generalized lipodystrophy under immune checkpoint inhibition

Br J Dermatol.

Haddad N, Vidal-Trecan T, Baroudjian B, Zagdanski AM, Arangalage D, Battistella M, Gautier JF, Lebbe C, Delyon J, PATIO group

doi: 10.1111/bjd.18124.

Melanoma and Skin Cancer

The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma

Melanoma Res.

Hanna DL, Law SJ, Merrick SA, Heptinstall L, Bass P, Dupont P, Sheri A

doi: 10.1097/CMR.0000000000000651.

Melanoma and Skin CancerImmunotherapy

Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet's-Like Infiltrate

JAMA Dermatol.

Parekh V, Gangadhar T, Kreider KL, Elenitsas R, Chu EY

doi: 10.1001/jamadermatol.2017.

RECOMMENDED

Melanoma and Skin Cancer

Spontaneous Hair Repigmentation in an 80-Year-Old Man: A Case of Melanoma-Associated Hair Repigmentation and Review of the Literature

Am J Dermatopathol.

Chan C, Magro CM, Pham AK, LeBlanc RE, Yan S, Barton DT, Pace NC, Chapman MS, Momtahen S

doi: 10.1097/DAD.

Melanoma and Skin Cancer

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report

BMC Cancer.

Ozaki Y, Shindoh J, Miura Y, Nakajima H, Oki R, Uchiyama M, Masuda J, Kinowaki K, Kondoh C, Tanabe Y, Tanaka T, Haruta S, Ueno M, Kitano S, Fujii T, Udagawa H, Takano T

doi: 10.1186/s12885-017-3785-4.

Melanoma and Skin Cancer

[Regression of cutaneous basal cell and squamous cell carcinoma under pembrolizumab]

Ann Dermatol Venereol.

Delaitre L, Martins-Héricher J, Truchot E, Denis D, Prophette B, Maillard H, Bénéton-Benhard N

doi: 10.1016/j.annder.2019.10.031.

Melanoma and Skin Cancer

Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature

Melanoma Res.

Kosche C, Stout M, Sosman J, Lukas RV, Choi JN

doi: 10.1097/CMR.0000000000000642.

Related content

Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors

Neoadjuvant Immunotherapy with combined Ipilimumab and Nivolumab in Melanoma Patients with Primary or In-transit Disease

Acquired generalized lipodystrophy under immune checkpoint inhibition

The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma

Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet's-Like Infiltrate

Spontaneous Hair Repigmentation in an 80-Year-Old Man: A Case of Melanoma-Associated Hair Repigmentation and Review of the Literature

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report

[Regression of cutaneous basal cell and squamous cell carcinoma under pembrolizumab]

Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature